Meng X, Min Q, Wang J-Y. B cell lymphoma. Adv Exp Med Biol. 2020;1254:161–81.

Article  CAS  PubMed  Google Scholar 

Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584–90.

Article  PubMed  Google Scholar 

Niu T, Liu T. Advances in the target therapy of hematological malignancies. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45:642–6.

CAS  PubMed  Google Scholar 

da Cunha-Bang C, Niemann CU. Targeting Bruton’s tyrosine kinase across B-cell malignancies. Drugs. 2018;78:1653–63.

Article  PubMed  Google Scholar 

Alu A, Lei H, Han X, Wei Y, Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15:138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network. Guidelines Detail [Internet]. NCCN® Guidelines for B-cell lymphomas. [cited 2023 Aug 31]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480

Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO). Consensus of Chinese experts on Bruton tyrosine kinase inhibitors in treatment of B cell malignant tumors. J Leukemia Lymphoma. 2022;31(9):513–26. https://doi.org/10.3760/cma.j.cn115356-20220718-00211.

Article  Google Scholar 

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020:336–45.

Article  Google Scholar 

Research C for DE and. FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma. FDA [Internet]. 2023 [cited 2023 May 16]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma

Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.

Article  CAS  PubMed  Google Scholar 

Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659–67.

Article  CAS  PubMed  Google Scholar 

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am J Hematol. 2023;98(4):571–9.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135:1204–13.

Article  PubMed  PubMed Central  Google Scholar 

Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014;39:483–519.

PubMed  PubMed Central  Google Scholar 

Brukinsa® [package insert]. Beijing China: BeiGene Co. Ltd; 2019 November.

Calquence® [package insert]. AstraZeneca Gaithersburg MD. November 2019.

Imbruvica [package insert] Sunnyvale, California: Pharmacyclics, Inc. 2014.

Lovell AR, Jammal N, Bose P. Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. Ther Adv Hematol. 2022;13:20406207221116576.

Article  Google Scholar 

CALQUENCE® (acalabrutinib) capsules, for oral use. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf

Shen J, Liu J. Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: a mini-review. Front Oncol. 2022;12:1034668.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833-843.e5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Li Y, Zhuang Z, Wang W, Wei C, Zhao D, et al. Preliminary evaluation of zanubrutinib-containing regimens in dlbcl and the cerebrospinal fluid distribution of Zanubrutinib: a 13-Case Series. Frontiers in Oncology [Internet]. 2021 [cited 2023 Mar 11];11. Available from: https://doi.org/10.3389/fonc.2021.760405

Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363:240–52.

Article  CAS  PubMed  Google Scholar 

Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of Zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62:7923–40.

Article  CAS  PubMed  Google Scholar 

Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Cultrera JL, et al. Phase 2 study of Zanubrutinib in BTK inhibitor-intolerant patients (Pts) with relapsed/refractory B-cell malignancies. Blood. 2021;138:1410.

Article  Google Scholar 

Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14:1329–44.

Article  CAS  PubMed  Google Scholar 

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

Article  CAS  PubMed  Google Scholar 

Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: a continuing evolution in care. Blood Rev. 2022;54: 100930.

Article  PubMed  Google Scholar 

Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

Article  PubMed  PubMed Central  Google Scholar 

Alshemmari SH, Siddiqui MA, Pandita R, Osman HY, Cherif H, O’Brien S, et al. Evidence-based management of chronic lymphocytic leukemia: consensus statements from the Gulf region. Acta Haematol. 2023. https://doi.org/10.1159/000531675.

Article  PubMed  Google Scholar 

Molica S, Rossi M, Allsup D. Consensus statements highlight the need of harmonizing CLL management worldwide. Acta Haematol. 2023. https://doi.org/10.1159/000533349

Article  PubMed  Google Scholar 

Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031–43.

Article  CAS  PubMed  Google Scholar 

Small S, Ma S. Frontline treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): targeted therapy vs. chemoimmunotherapy. Curr Hematol Malig Rep. 2021;16:325–35.

Article  PubMed  Google Scholar 

O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.

Article  PubMed  Google Scholar 

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440–50.